

Actor portrayal

**Ekterly**<sup>®</sup>  
(sebetralstat) tablets 300 mg

## Your guide to getting your patients started on EKTERLY

When starting patients on EKTERLY, you and your staff can reference the checklist below to ensure a positive onboarding experience.



### Complete and submit the Start Form

- Access the Start Form on [EKTERLYHCP.com/start-form](https://EKTERLYHCP.com/start-form)
- Fax the completed form to 1-844-432-9525 or submit online by visiting [KalVistaCaresEnroll.com](https://KalVistaCaresEnroll.com)



### Provide your patients with EKTERLY resources

- Resources such as the patient brochure and [EKTERLY.com](https://EKTERLY.com) can help your patients learn more about their treatment journey with EKTERLY



### Utilize KalVista Cares™ for additional support

- KalVista Cares Care Managers can provide answers, resources, and tools to help your patients navigate their treatment journey effectively
  - Learn more by visiting [EKTERLYHCP.com/prescribe-ekterly](https://EKTERLYHCP.com/prescribe-ekterly)



### Ensure necessary paperwork is completed and submitted to secure approval

- This includes Prior Authorization and the Letter of Medical Necessity

#### INDICATION

EKTERLY<sup>®</sup> (sebetralstat) is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

#### IMPORTANT SAFETY INFORMATION

**Adverse reactions:** The most commonly reported adverse reaction was headache.

Please see additional Important Safety Information on the following page.  
Please see accompanying full [Prescribing Information](#).

## INDICATION

EKTERLY® (sebetralstat) is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

## IMPORTANT SAFETY INFORMATION

**Adverse reactions:** The most commonly reported adverse reaction was headache.

**Drug interactions:** EKTERLY is a substrate of CYP3A4. Concomitant use of EKTERLY with a strong CYP3A4 inhibitor increases sebetralstat exposure, which may increase the risk of sebetralstat adverse reactions. Avoid use of EKTERLY with strong CYP3A4 inhibitors and reduce the dose of EKTERLY to one dose of 300 mg (one tablet) with moderate CYP3A4 inhibitors. Concomitant use of EKTERLY with a strong or moderate CYP3A4 inducer decreases sebetralstat exposure, which may decrease efficacy. The use of EKTERLY with strong or moderate CYP3A4 inducers is not recommended.

**Use in specific populations:** Avoid use of EKTERLY in patients with severe hepatic impairment (Child-Pugh Class C). The recommended dosage of EKTERLY is one dose of 300 mg (one tablet) in patients with moderate hepatic impairment (Child-Pugh Class B).

There are no available data on EKTERLY in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. There are no data on the presence of sebetralstat or its metabolite in human milk, the effects on the breastfed infant, or the effects on milk production.

The safety and effectiveness of EKTERLY in pediatric patients aged under 12 years of age have not been established.

To report SUSPECTED ADVERSE REACTIONS, contact KalVista Pharmaceuticals, Inc. at **1-855-258-4782** or FDA at **1-800-FDA-1088** or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

Please see the full [Prescribing Information](#).